Pfizer (Germany) Top Management
PFE Stock | EUR 23.60 0.03 0.13% |
Pfizer employs about 39 people. The company is managed by 25 executives with a total tenure of roughly 214 years, averaging almost 8.0 years of service per executive, having 1.56 employees per reported executive. Evaluation of Pfizer's management performance can provide insight into the firm performance.
John Young President Group President - Pfizer Innovative Health and Angela Hwang |
Frank DAmelio President Chief Financial Officer, Executive Vice President - Business Operations and Global Supply |
Pfizer |
Pfizer Management Team Effectiveness
Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.Pfizer Workforce Comparison
Pfizer Inc is considered to be number one stock in number of employees category among its peers. The total workforce of Other industry is at this time estimated at about 13,932. Pfizer adds roughly 39.0 in number of employees claiming only tiny portion of all equities under Other industry.
Pfizer Inc Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Pfizer Inc Price Series Summation is a cross summation of Pfizer price series and its benchmark/peer.
Pfizer Notable Stakeholders
A Pfizer stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pfizer often face trade-offs trying to please all of them. Pfizer's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pfizer's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
John Young | Group President - Pfizer Innovative Health and Angela Hwang | Profile | |
Frank DAmelio | Chief Financial Officer, Executive Vice President - Business Operations and Global Supply | Profile | |
Douglas Lankler | Executive Vice President General Counsel | Profile | |
Dawn Rogers | Chief Human Resource Officer, Executive Vice President | Profile | |
Mikael Dolsten | Chief Scientific Officer, President - Worldwide Research, Development and Medical | Profile | |
Lidia Fonseca | Executive Vice President, Chief Technology Officer and Digital Officer | Profile | |
Alexander Mackenzie | Executive Vice President Chief Development Officer | Profile | |
Sally Susman | Chief Corporate Affairs Officer, Executive Vice President | Profile | |
Rady Johnson | Chief Compliance, Quality and Risk Officer, Executive Vice President | Profile | |
Albert Bourla | Group President - Vaccines, Oncology and Consumer Healthcare Business | Profile | |
Angela Hwang | Group President, Pfizer Biopharmaceuticals Group | Profile | |
Helen Hobbs | Independent Director | Profile | |
Shantanu Narayen | Lead Independent Director | Profile | |
Wyllie Cornwell | Independent Director | Profile | |
Suzanne Johnson | Independent Director | Profile | |
Susan Hockfield | Independent Director | Profile | |
Dan Littman | Independent Director | Profile | |
James Kilts | Independent Director | Profile | |
James Quincey | Independent Director | Profile | |
Joseph Echevarria | Independent Director | Profile | |
Scott Gottlieb | Independent Director | Profile | |
Ronald Blaylock | Independent Director | Profile | |
Jennifer Damico | Senior Vice President Principal Accounting Officer, Controller | Profile | |
Susan DesmondHellmann | Director | Profile | |
Gordon Loh | Senior Vice President Corporate Audit | Profile |
About Pfizer Management Performance
The success or failure of an entity such as Pfizer Inc often depends on how effective the management is. Pfizer management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pfizer management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pfizer management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the presentation of Pfizer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pfizer's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Pfizer's management manipulating its earnings.
Pfizer Workforce Analysis
Traditionally, organizations such as Pfizer use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pfizer within its industry.Pfizer Manpower Efficiency
Return on Pfizer Manpower
Revenue Per Employee | 2.6B | |
Revenue Per Executive | 4B | |
Net Income Per Employee | 804.4M | |
Net Income Per Executive | 1.3B |
Complementary Tools for Pfizer Stock analysis
When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
CEOs Directory Screen CEOs from public companies around the world | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |